Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Issues in Early Stage NSCLC from ASCO 2007
Author
Howard (Jack) West, MD

While post-operative chemotherapy has emerged as the standard treatment for patients with stage II and resected IIIA NSCLCC, and some patients with stage IB disease, trials conducted over the past few years are providing information about the option of treating with initial chemotherapy before surgery. A couple of trials were presented at ASCO this year that did not demonstrate a significant survival benefit of pre-operative chemo compared with no treatment. The Southwest Oncology Group, in which I participate, presented more mature data from the SWOG 9900 trial of pre-operative chemo with carbo/taxol for three cycles vs. going straight to surgery (abstract here), and the findings with longer follow-up are now close to showing statistical significance to a similar degree as what is seen with post-operative chemo, but even if it became positive, the evidence for a post-op chemo standard has been stronger and would remain the more common approach. In the meantime, however, it remains a consideration for a subset of patients, but there isn’t much enthusiasm for studies directly comparing pre-op vs. post-op chemo at this point. One area in which pre-operative chemo remains appealing is a “window of opportunity” giving a few weeks of a targeted therapy to see the rapid clinical effects and then remove the tumor and see if the treatment had targeted effects on the tumor.

In addition to chemo as a treatment after surgery, a group from Europe looked at a vaccine to a protein called MAGE-A3 that is expressed on about 1/3 of NSCLC tumors (abstract here). They ran a randomized phase II study with about 180 patients (who had all been found to have MAGE-A3 expression on their tumor) in which 2/3 received the active vaccine and 1/3 received a placebo after surgery for stage IB or II NSCLC. They found that there was about a 25% improvement in progression-free survival among the recipients of the vaccine compared with the placebo group, although this difference wasn't quite statistically significant. While it wasn't quite statistically significant, it did generate major interest among the oncologists present, and even more interest, I think, among the Wall Street analysts covering the meeting. The maker of the vaccine, GlaxoSmithKline, is starting a larger phase III trial in the adjuvant setting that is just getting started.

Next Previous link

Previous PostNext Post

Related Content

Image
Clinical Trials Storytelling 2025
Article
GRACE is pleased to introduce three amazing individuals participating in the 2024-25 GRACE Clinical Trials Experiences Storytelling Program
Article
Imagine your body's defense system, the lymphatic system, suddenly turning against you. This is the reality for those facing lymphoma, a cancer of the immune system's crucial network. This article delves into the complexities of lymphoma, exploring its various forms, from the aggressive to the indolent, and examining the latest breakthroughs in treatment, including the groundbreaking POLARIX trial and cutting-edge therapies for relapsed cases. Whether you're a patient, a loved one, or simply curious about this complex disease, this comprehensive overview will provide valuable insights into the current state of lymphoma care and the promising future of research.
Image
Melanoma Video Library
Video
In these videos, Dr. Autumn Starnes gives an overview of melanoma's prevalence and risk factors. She also discusses the ABCDE method of self-screening for skin cancer, common misconceptions regarding people of color, and melanoma, and how a person can lower their risk of developing melanoma, among other relevant topics regarding melanoma.  To watch the complete playlist, click here. 

Forum Discussions

Can SCLC also be treated with targeted therapy?

Hi amitchouhan,

Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...

I was searching for this, Thank you so much for the info.

Glad to help.  FYI, I just edited the link, which has the agenda and links to oncologists' bios. Plus, the link is also on our home page, https://cancergrace.org/

Hope to see...

Recent Comments

JOIN THE CONVERSATION
Glad to help.  FYI, I just…
By JanineT GRACE … on
I was searching for this,…
By LilahStapleton on
Hi and welcome.  I'm sorry…
By JanineT GRACE … on
Hi amitchouhan,

Welcome to…
By JanineT GRACE … on